NASDAQ · HALO
Healthcare · Biotechnology
$130.91
Down-$0.27 (-0.21%)
Updated Nov 2, 2026, 6:46 AM
SID Score
7.8/10
Composite research score
Smart Money
47/100
Neutral
Price performance · HALO
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
HALO closed at $130.91 after 20 trading sessions, up 20.87% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $132.66 | $134.00 | $130.305 | $130.91 | 1.4M |
| Oct 29, 2026 | $131.06 | $132.55 | $130.09 | $131.18 | 1.88M |
| Oct 28, 2026 | $126.78 | $130.24 | $126.25 | $130.03 | 1.73M |
| Oct 27, 2026 | $127.21 | $128.94 | $126.13 | $128.50 | 1.7M |
| Oct 26, 2026 | $126.03 | $128.11 | $126.03 | $128.01 | 1.24M |
| Oct 23, 2026 | $124.54 | $126.23 | $123.74 | $125.63 | 1.53M |
| Oct 22, 2026 | $124.72 | $124.91 | $121.6174 | $124.54 | 5.1M |
| Oct 21, 2026 | $123.90 | $125.43 | $122.71 | $124.83 | 1.72M |
| Oct 20, 2026 | $123.54 | $125.10 | $123.00 | $124.37 | 2.15M |
| Oct 19, 2026 | $121.72 | $123.60 | $121.685 | $122.50 | 1.89M |
| Oct 16, 2026 | $122.19 | $122.445 | $120.1928 | $121.84 | 2.08M |
| Oct 15, 2026 | $118.35 | $122.33 | $117.38 | $121.51 | 2.47M |
| Oct 14, 2026 | $109.90 | $119.21 | $109.42 | $116.82 | 3.77M |
| Oct 13, 2026 | $111.92 | $111.92 | $108.80 | $109.62 | 1.78M |
| Oct 12, 2026 | $110.19 | $112.43 | $109.96 | $111.08 | 1.66M |
| Oct 9, 2026 | $109.70 | $112.65 | $109.70 | $110.42 | 1.85M |
| Oct 8, 2026 | $109.41 | $110.64 | $107.41 | $109.84 | 2.49M |
| Oct 7, 2026 | $111.62 | $113.995 | $110.1572 | $110.79 | 2.18M |
| Oct 6, 2026 | $108.87 | $111.245 | $107.43 | $109.72 | 1.77M |
| Oct 5, 2026 | $109.62 | $109.87 | $107.68 | $108.31 | 1.86M |
The latest Smart Investors Daily articles mentioning HALO.
Company
Market Activity
Research & News
HALO research
Company profile and research snapshot.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 13, 2026 | TD Cowen | Buy | — |
| Oct 8, 2026 | HC Wainwright & Co. | Buy | — |
| Oct 8, 2026 | JP Morgan | Neutral | — |
| Sep 2, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 7, 2026 | Citizens | Market Outperform | — |
No generated briefing is available yet.
Yahoo · Oct 29, 2026
Is EXEL a good stock to buy? We came across a bullish thesis on Exelixis, Inc. on TradersPro’s Substack. In this article, we will summarize the bulls’ thesis on EXEL. Exelixis, Inc.’s share was trading at $66.28 as of October 28th 2026. EXEL’s trailing and forward P/E were 20.62 and 15.25 respectively according to Yahoo Finance. This […]
Yahoo · Oct 29, 2026
Halozyme Therapeutics (HALO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Yahoo · Oct 28, 2026
For questions about this article or underlying research, email [email protected].
Yahoo · Oct 27, 2026
Renaissance Investment Management, an investment management company, released its Q3 2026 investor letter for “Large Cap Growth Strategy.” The letter can be downloaded here. Stocks showed modest gains in Q3, with the S&P 500 up 2.3%. Energy, Technology, and Health Care sectors excelled, while Utilities, Industrials, Real Estate, and Consumer Discretionary lagged. Market breadth was […]
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning HALO.
